BiotechTube

U3-1287 + Erlotinib + Placebo

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NSCLC (Advanced Non-small Cell Lung Cancer)

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Trial Timeline

Sep 1, 2010 → Nov 23, 2013

NCT ID
NCT01211483

About U3-1287 + Erlotinib + Placebo

U3-1287 + Erlotinib + Placebo is a phase 1/2 stage product being developed by Daiichi Sankyo for NSCLC (Advanced Non-small Cell Lung Cancer). The current trial status is completed. This product is registered under clinical trial identifier NCT01211483. Target conditions include NSCLC (Advanced Non-small Cell Lung Cancer).

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT01211483Phase 1/2Completed

Competing Products

20 competing products in NSCLC (Advanced Non-small Cell Lung Cancer)

See all competitors
ProductCompanyStageHype Score
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/CarboplatinWuXi BiologicsPhase 3
74
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
BBP-398 + osimertinibLianBioPhase 1
25
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)BioAtlaPhase 1/2
33
YH42946YuhanPhase 1/2
41
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + OsimertinibDaiichi SankyoPhase 1
33
DS-1205c + OsimertinibDaiichi SankyoPhase 1
33
Datopotamab deruxtecan (Dato-DXd) + DocetaxelDaiichi SankyoPhase 3
77
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789Daiichi SankyoPhase 1
33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + CisplatinDaiichi SankyoPhase 1
33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)Daiichi SankyoPhase 1
33
CS-7017 + erlotinibDaiichi SankyoPhase 2
52
gilteritinibAstellas PharmaPhase 1
33
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
52
naquotinib + midazolamAstellas PharmaPhase 1
33
OSI-906 + Erlotinib + PlaceboAstellas PharmaPhase 2
52
ExisulindAstellas PharmaPhase 1/2
41
naquotinibAstellas PharmaPhase 1
33
ASP8273Astellas PharmaPhase 2
52
TarcevaAstellas PharmaPhase 1
33

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85